Barriat Sebastien, Poirrier Annelise, Malgrange Brigitte, Lefebvre Philippe
Adv Otorhinolaryngol. 2010;67:6-13. doi: 10.1159/000262592. Epub 2009 Nov 25.
Insertion of an electrode array into the cochlea produces immediate damage to the inner ear, which is responsible for a hearing loss. In addition, a delayed hearing loss can be observed. In order to maximize hearing preservation after insertion of an electrode and to enhance the performance of the cochlear implant, it has been proposed to deliver pharmacological agents to the inner ear. Molecules can be administered locally to the inner ear through a direct perilymphatic perfusion or through the round window membrane. These modalities of treatment have already been successfully applied to some patients with inner ear diseases. In this paper, we will review some basic aspects of drug delivery to the inner ear to prevent the degeneration of the neurosensory hair cells and auditory neurons, and the actual applicability to humans in order to maintain hearing function after the insertion of electrodes of a cochlear implant.
将电极阵列插入耳蜗会立即对内耳造成损伤,这会导致听力丧失。此外,还可观察到迟发性听力丧失。为了在插入电极后最大程度地保留听力并提高人工耳蜗的性能,有人提出向内耳输送药物制剂。分子可通过直接外淋巴灌注或通过圆窗膜局部给药至内耳。这些治疗方式已成功应用于一些内耳疾病患者。在本文中,我们将综述向内耳给药以防止神经感觉毛细胞和听觉神经元退化的一些基本方面,以及在人类中的实际适用性,以便在人工耳蜗电极插入后维持听力功能。